Exenatide oral - Oramed

Drug Profile

Exenatide oral - Oramed

Alternative Names: ORMD-0901; ORMD-901

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 31 Oct 2017 European Patent Organisation issues notice of intent to grant a patent to Oramed for Exenatide oral
  • 12 May 2017 Oramed's oral exenatide is still at phase II development stage in Israel and preclinical stage in USA for Type-2 diabetes mellitus (Oramed Corporate presentation, May 2017)
  • 09 May 2017 Oramed has patent protection for exenatide in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top